Transduction of nonhuman primate brain with adeno-associated virus serotype 1: vector trafficking and immune response.
about
Biology of adeno-associated viral vectors in the central nervous systemPreclinical safety of RNAi-mediated HTT suppression in the rhesus macaque as a potential therapy for Huntington's diseaseSynthetic biology and therapeutic strategies for the degenerating brain: Synthetic biology approaches can transform classical cell and gene therapies, to provide new cures for neurodegenerative diseasesGene-based therapy of Parkinson's Disease: Translation from animal model to human clinical trial employing convection enhanced deliveryGene therapy for metachromatic leukodystrophy.Cerebral infusion of AAV9 vector-encoding non-self proteins can elicit cell-mediated immune responses.Convection-enhanced delivery of AAV2-PrPshRNA in prion-infected miceDifferential transduction following basal ganglia administration of distinct pseudotyped AAV capsid serotypes in nonhuman primatesAAV provides an alternative for gene therapy of the peripheral sensory nervous system.Adeno-associated virus serotypes 1, 8, and 9 share conserved mechanisms for anterograde and retrograde axonal transport.Direct gene transfer to the CNS prevents emergence of neurologic disease in a murine model of mucopolysaccharidosis type I.The AAV vector toolkit: poised at the clinical crossroadsAdeno-associated virus serotype 9 transduction in the central nervous system of nonhuman primatesCorrection of brain oligodendrocytes by AAVrh.10 intracerebral gene therapy in metachromatic leukodystrophy mice.Merits of combination cortical, subcortical, and cerebellar injections for the treatment of Niemann-Pick disease type ARobust Long-term Transduction of Common Marmoset Neuromuscular Tissue With rAAV1 and rAAV9.Dose-dependent Toxicity of Humanized Renilla reniformis GFP (hrGFP) Limits Its Utility as a Reporter Gene in Mouse MuscleGene therapy for misfolding protein diseases of the central nervous system.Widespread AAV1- and AAV2-mediated transgene expression in the nonhuman primate brain: implications for Huntington's disease.Strategies for targeting primate neural circuits with viral vectors.Recombinant adeno-associated virus type 2 pseudotypes: comparing safety, specificity, and transduction efficiency in the primate striatum. Laboratory investigation.Deimmunization for gene therapy: host matching of synthetic zinc finger constructs enables long-term mutant Huntingtin repression in mice.Functional effects of AAV2-GDNF on the dopaminergic nigrostriatal pathway in parkinsonian rhesus monkeys.Adeno-associated virus type 6 is retrogradely transported in the non-human primate brain.AAV9-mediated expression of a non-self protein in nonhuman primate central nervous system triggers widespread neuroinflammation driven by antigen-presenting cell transduction.Antisense gene silencing: therapy for neurodegenerative disorders?Viral vector-mediated gene transfer for CNS disease.Progress and prospects: Immunobiology of gene therapy for neurodegenerative disease: prospects and risks.Gene therapy for Parkinson's disease: where are we now and where are we going?Optogenetics in the nonhuman primate.A next step in adeno-associated virus-mediated gene therapy for neurological diseases: regulation and targeting.Adeno-associated virus vectors and neurological gene therapy.Gene therapy for the neurological manifestations in lysosomal storage disorders.Huntingtin-lowering strategies in Huntington's disease: antisense oligonucleotides, small RNAs, and gene editing.Preclinical toxicity evaluation of AAV for pain: evidence from human AAV studies and from the pharmacology of analgesic drugs.Lack of humoral immune response to the tetracycline (Tet) activator in rats injected intracranially with Tet-off rAAV vectors.Direct Intracranial Injection of AAVrh8 Encoding Monkey β-N-Acetylhexosaminidase Causes Neurotoxicity in the Primate Brain.High cerebrospinal fluid levels of interleukin-10 attained by AAV in dogs.Evaluation of the expression pattern of rAAV2/1, 2/5, 2/7, 2/8, and 2/9 serotypes with different promoters in the mouse visual cortex.Axonal transport of adeno-associated viral vectors is serotype-dependent.
P2860
Q21129328-BA982720-3BDF-4B6D-8BC7-3C0EBC9DBE76Q24626259-05451FF8-331F-4B53-9BFF-66677B60F266Q26830610-0AE23D46-C8AD-47E4-99DB-E7234A046605Q26851517-8067044D-C50F-4AC6-B59E-ADC5423DA902Q30357745-7BF41A98-2FF7-470A-97DC-BE222BAFE359Q30531601-062A36EA-D8EA-46BC-8DDB-DA9C858C7640Q33670676-AD354C0C-4A50-4909-9135-B1BCB5DCAC6AQ33731243-B6E9DF45-2A76-4625-AF53-0B748365B42CQ33822179-2E415370-FE57-43A3-8D99-5003BD3E2705Q34063628-854B393E-D30B-4E5E-9878-965714F3C1A9Q35559945-8AB4D40D-BB7A-4DB0-B5E3-5D9027F1466BQ35876224-CD3E5663-9F0A-4324-B36B-DD40928EA1C4Q35892068-D512DE70-ADF5-4BFD-8DD5-7B17CC3F1B97Q36147497-9EDEE8FC-C3CD-46DE-AE95-097A1DA55456Q36299764-4A4F2D7D-B266-4F68-A23A-97EA3DFA2855Q36757156-ED50A5D1-5DEC-4ADD-9823-277892B1780BQ36832228-C23D0E3B-C449-44DE-8C3E-2D08CC21E6B9Q36983203-64D196F1-2775-4FF7-99D2-86021036B934Q37051728-6B0C9DA5-8425-4AA3-A1C6-1DF202E84F6BQ37127728-88265E1B-02B8-4FD4-9897-3DA1950A02A0Q37171255-7C0B8610-4527-4BE3-922D-6806E2925AB8Q37237181-0BF555B6-87D4-4404-9324-E6D36FBD99EDQ37301013-3922AA65-6D31-4B6C-81CE-401AB1D7CD9EQ37374468-455B394A-6688-4BD9-8560-1B5AAAC73A3BQ37571781-CB7CF2FB-8619-4B2F-A0FB-A6AF8873EA56Q37585001-03A8F688-309D-4334-90AA-B91C732E3A64Q37687420-31A9130E-8629-45C0-BB3C-633A3DB2D1B4Q37690581-488BC287-76BC-4631-B606-71B2E168BB23Q37810994-BFF31F7C-F877-4810-A9F2-252AC27B3C9AQ37985026-7BFAE0FF-F54F-495C-9515-12A4525C1243Q38075068-8A1A1D62-F7BF-47A5-B231-956A19ACB65FQ38190041-D3F9DBD0-C543-4136-8661-3F6C6BB9FE7FQ38200599-3A9CEFB8-F006-4AC6-9E9D-F1984C90D5C3Q38244104-C1BD29AA-F40D-446E-B692-ECAB21A5C6C8Q38245677-BDDF6648-1CEC-46DC-9F09-92411F593D09Q39737981-6685CE4C-C601-4A4A-8202-9B39FF3EB95CQ40360298-92BFA4B9-0596-4144-B381-CBF7963CB71AQ41575309-F35B2E50-647A-4924-9226-D6AC0DF733F4Q41716240-BA227D64-DA4E-499C-92ED-0B9A5B21CDC5Q41919978-40A5F665-89B1-40F1-B235-5935BF48C6BB
P2860
Transduction of nonhuman primate brain with adeno-associated virus serotype 1: vector trafficking and immune response.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
2009年论文
@zh
2009年论文
@zh-cn
name
Transduction of nonhuman prima ...... afficking and immune response.
@en
Transduction of nonhuman prima ...... afficking and immune response.
@nl
type
label
Transduction of nonhuman prima ...... afficking and immune response.
@en
Transduction of nonhuman prima ...... afficking and immune response.
@nl
prefLabel
Transduction of nonhuman prima ...... afficking and immune response.
@en
Transduction of nonhuman prima ...... afficking and immune response.
@nl
P2093
P2860
P356
P1433
P1476
Transduction of nonhuman prima ...... afficking and immune response.
@en
P2093
Beverly L Davidson
Hanna Mirek
Jodi L McBride
John Bringas
John Forsayeth
Keith Munson
Krystof S Bankiewicz
Phil Pivirotto
Piotr Hadaczek
P2860
P304
P356
10.1089/HUM.2008.151
P50
P577
2009-03-01T00:00:00Z